Real-time Estimate
Cboe BZX
12:31:28 27/06/2024 am IST
|
5-day change
|
1st Jan Change
|
11.12
USD
|
-5.24%
|
|
-2.45%
|
-20.60%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,840
|
372
|
98.27
|
766.3
|
655.6
|
-
|
-
|
Enterprise Value (EV)
1 |
1,840
|
372
|
98.27
|
766.3
|
573.4
|
526.9
|
538.3
|
P/E ratio
|
-14.1
x
|
-5.2
x
|
-0.94
x
|
-6.56
x
|
-5
x
|
-4.64
x
|
-4.42
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
112
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
92.2
x
|
EV / EBITDA
|
-85.5
x
|
-5.22
x
|
-0.92
x
|
-7.33
x
|
-4.26
x
|
-3.02
x
|
-2.49
x
|
EV / FCF
|
-92.4
x
|
-7.12
x
|
-1.19
x
|
-9.15
x
|
-7.14
x
|
-3.93
x
|
-3.59
x
|
FCF Yield
|
-1.08%
|
-14%
|
-83.9%
|
-10.9%
|
-14%
|
-25.4%
|
-27.9%
|
Price to Book
|
-
|
-
|
0.5
x
|
3.04
x
|
2.76
x
|
2.09
x
|
-
|
Nbr of stocks (in thousands)
|
38,274
|
39,745
|
40,110
|
54,622
|
55,893
|
-
|
-
|
Reference price
2 |
48.08
|
9.360
|
2.450
|
14.03
|
11.73
|
11.73
|
11.73
|
Announcement Date
|
17/03/21
|
28/02/22
|
09/03/23
|
11/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
5.836
|
EBITDA
1 |
-
|
-21.52
|
-71.33
|
-106.6
|
-104.6
|
-134.8
|
-174.2
|
-216.2
|
EBIT
1 |
-
|
-21.53
|
-71.49
|
-107
|
-105
|
-135.3
|
-162.4
|
-182.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,130.5%
|
Earnings before Tax (EBT)
1 |
-
|
-22.12
|
-71.1
|
-104.8
|
-96.66
|
-130.9
|
-159.7
|
-175.9
|
Net income
1 |
-4.316
|
-23.99
|
-71.1
|
-104.8
|
-96.66
|
-130.9
|
-159.7
|
-175.9
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,014.81%
|
EPS
2 |
-0.6000
|
-3.420
|
-1.800
|
-2.620
|
-2.140
|
-2.348
|
-2.529
|
-2.653
|
Free Cash Flow
1 |
-
|
-19.92
|
-52.26
|
-82.43
|
-83.73
|
-80.33
|
-134
|
-150
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,570.25%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/10/20
|
17/03/21
|
28/02/22
|
09/03/23
|
11/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-21.68
|
-23.17
|
-33.21
|
-23.13
|
-27.12
|
-29.5
|
-21.5
|
-23.25
|
-30.33
|
-34.25
|
-33.98
|
-35.87
|
-39.31
|
-
|
-
|
EBIT
1 |
-21.76
|
-23.25
|
-33.29
|
-23.22
|
-27.22
|
-29.6
|
-21.6
|
-23.34
|
-30.42
|
-34.34
|
-32.45
|
-33.67
|
-35.5
|
-34.14
|
-38
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-21.64
|
-23.03
|
-32.86
|
-22.72
|
-26.18
|
-28.29
|
-20.1
|
-21.5
|
-26.77
|
-30.97
|
-31.82
|
-32.92
|
-35.16
|
-35
|
-38
|
Net income
1 |
-21.64
|
-23.03
|
-32.86
|
-22.72
|
-26.18
|
-28.29
|
-20.1
|
-21.5
|
-26.77
|
-30.97
|
-31.82
|
-32.92
|
-35.16
|
-35
|
-38
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5400
|
-0.5800
|
-0.8200
|
-0.5700
|
-0.6500
|
-0.7000
|
-0.4900
|
-0.4800
|
-0.4900
|
-0.5600
|
-0.5668
|
-0.5874
|
-0.6298
|
-0.6000
|
-0.6500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/02/22
|
09/05/22
|
09/08/22
|
08/11/22
|
09/03/23
|
09/05/23
|
08/08/23
|
07/11/23
|
11/03/24
|
08/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
82.2
|
129
|
117
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-19.9
|
-52.3
|
-82.4
|
-83.7
|
-80.3
|
-134
|
-150
|
ROE (net income / shareholders' equity)
|
-
|
-14.6%
|
-22.8%
|
-43.5%
|
-42.8%
|
-63.8%
|
-78.7%
|
-73.6%
|
ROA (Net income/ Total Assets)
|
-
|
-14%
|
-22.3%
|
-41%
|
-39.2%
|
-49.2%
|
-48.2%
|
-
|
Assets
1 |
-
|
171.4
|
319.3
|
255.8
|
246.3
|
266.1
|
331.2
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
4.900
|
4.620
|
4.250
|
5.620
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-2.050
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.06
|
1.58
|
0.36
|
-
|
1
|
1.33
|
2
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
34.27%
|
Announcement Date
|
30/10/20
|
17/03/21
|
28/02/22
|
09/03/23
|
11/03/24
|
-
|
-
|
-
|
Last Close Price
11.73
USD Average target price
28
USD Spread / Average Target +138.70% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.60% | 656M | | +26.31% | 52.73B | | +37.49% | 39B | | -9.24% | 38.52B | | +29.13% | 30.38B | | -12.26% | 26.39B | | +10.76% | 26.08B | | +45.07% | 14.15B | | +32.44% | 12.6B | | -6.03% | 11.51B |
Other Biotechnology & Medical Research
|